Ann: DMX-200 CLARITY COVID-19 Study Approval in India, page-21

Hi Kdwc,

It’s been on hold a long time this trial with the Delta outbreak in India. They are obviously recovered to a point of functioning again on this one. Staff members becoming infected etc also. Never a good scenario, but vaccinations are making a difference.

I never doubted this wouldn’t go ahead & we have the Lead Investigator on Janssen’s (J&J) CREDENCE study that was groundbreaking in Diabetic Kidney Disease & Chronic Kidney Disease as a Lead Investigator on this Study also (which really is an extension on an existing ARB study (Telmisartan) but this one we will be using Candisartan + DMX-200).

I have no idea of what the Market thinks, but I agree that some may have sold some to fund SPP. Onwards & upwards.

Ph3 trials, & as much as we have some expensive monoclonal antibodies to treat patients early with COVID-19, even here in Australia they are limited to the most high risk patients on risk criteria. A few pills to keep patients out of hospital is far preferable.